Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 31

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 31
---
 number of shares of Common Stock outstanding as of April 14, 2025. Unless indicated otherwise, all share and per share information presented in this prospectus reflects the completion of the Reverse Stock Split. The Company’s historical financial statements included in this prospectus do not reflect the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Instead, each fractional share remaining after completion of the reverse share split that was less than a whole share was rounded down and canceled in exchange for an amount in cash (without interest or deduction) equal to the fraction of one share to which such stockholder would otherwise be entitled multiplied by the closing price of the Common Stock on The Nasdaq Capital Market on the last trading day immediately preceding the effectiveness of the Reverse Stock Split. The Reverse Stock Split was applied to all the Company’s outstanding Common Stock and therefore did not affect any shareholder’s ownership percentage of the shares, except for changes as a result of the elimination of fractional shares. The Reverse Stock Split did not alter the voting rights attached to the shares.On April 30, 2025, the Company received notice from Nasdaq that it had regained compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2).

Emerging Growth Company

We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements**

<div align='center'>16</div>

of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are required to comply with the new or revised financial accounting standards. The